# A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

> **NCT00487058** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Gimatecan

## Key facts

- **NCT ID:** NCT00487058
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2009-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00487058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00487058, "A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00487058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*